Jeffrey Zwicker

Isoquercetin as a PDI Inhibitor: Dose-Optimization and Patient Phenotyping

National Center for Complementary and Integrative Health · R01

Contact PI · $1.2M · Sloan-Kettering Inst Can Research

Biomarkers and Mechanisms in Cancer Associated Thrombosis

National Heart, Lung, and Blood Institute · U01

Contact PI · $4.3M · Beth Israel Deaconess Medical Center

Vascular Thiol Isomerases in Thrombosis

National Heart, Lung, and Blood Institute · R01

Contact PI · $817.6K · Beth Israel Deaconess Medical Center

Response to PQ12 - Using Thiol Isomerase Inhibitors to Diminish Cancer Induced Thrombosis

National Cancer Institute · R21

PI · $164.1K · Western New England University

A Study of Isoquercetin in People With Ovarian Cancer

Principal investigator · Recruiting · Phase 2

Memorial Sloan Kettering Cancer Center

Isoquercetin in Sickle Cell Anemia

Principal investigator · Withdrawn · Phase 2

Jeffrey Zwicker, MD

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Principal investigator · Completed · Phase 2

Dana-Farber Cancer Institute

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

Principal investigator · Completed · Phase 2, Phase 3

Jeffrey Zwicker, MD